Predictive models for drugs exhibiting negative food effects based on their biopharmaceutical characteristics

Drug Development and Industrial Pharmacy

Volumn 37, Issue 12, 2011, Pages 1429-1438

  Marasanapalle, Venugopal P ^a   Crison, John R ^b   Devarakonda, Krishna R ^c   Li, Xiaoling ^a   Jasti, Bhaskara R ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c MEDTRONIC INC   (United States)

Author keywords

biopharmaceutical properties; Caco 2 permeability; dissociation constant; negative food effects; Predictive model

Indexed keywords

ATENOLOL; CALCIUM ION; DICLOFENAC; DILTIAZEM; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IBUPROFEN; KETOPROFEN; NADOLOL; PRAVASTATIN; TACRINE; THEOPHYLLINE; TIMOLOL; VALSARTAN; ZIDOVUDINE;

ANIMAL TISSUE; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; CORRELATION ANALYSIS; DISSOCIATION CONSTANT; DRUG ABSORPTION; DRUG EFFECT; EMPIRICAL RESEARCH; FEMALE; FOOD; GASTROINTESTINAL TRACT; IN VITRO STUDY; INTESTINE MUCOSA PERMEABILITY; MALE; MULTIPLE REGRESSION; NONHUMAN; PH; POSTPRANDIAL STATE; PREDICTION; RAT; TREND STUDY;

ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; FEMALE; FOOD; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; MALE; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; RATS; RATS, WISTAR; REGRESSION ANALYSIS;

EID: 80955155279     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.584193     Document Type: Article

References (60)

1. Read NW, Sugden K. (1988). Gastrointestinal dynamics and pharmacology for the optimum design of controlled-release oral dosage forms. Crit Rev Ther Drug Carrier Syst, 4:221-263. (Pubitemid 18003661)
2. Vishwanathan S. (2005). The latest in POP (tablet) technology. Pharm Formulation Quality, 7:32-34.
3. Singh BN. (1999). Effects of food on clinical pharmacokinetics. Clin Pharmacokinet, 37:213-255. (Pubitemid 29452756)
4. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. (1999). Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet, 36:233-254. (Pubitemid 29178760)
5. CDER. (2002). Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. Vol. 2004-2005, FDA.
6. Marasanapalle VP, Crison JR, Ma J, Li X, Jasti BR. (2009). Investigation of some factors contributing to negative food effects. Biopharm Drug Dispos, 30:71-80.
7. Timmer CJ, Huisman JA. (2002). Effect of a standardized meal on the bioavailability of a single oral dose of tibolone 2.5 mg in healthy postmenopausal women. Pharmacotherapy, 22:310-315. (Pubitemid 34205169)
8. Li Z, Vachharajani NN, Krishna R. (2002). On the assessment of effects of food on the pharmacokinetics of drugs in early development. Biopharm Drug Dispos, 23:165-171. (Pubitemid 34578276)
9. Charman WN, Porter CJ, Mithani S, Dressman JB. (1997). Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci, 86:269-282. (Pubitemid 27113759)
10. Singh BN. (2005). A quantitative approach to probe the dependence and correlation of food-effect with aqueous solubility, dose/ solubility ratio, and partition coefficient (Log P) for orally active drugs administered as immediate-release formulations. Drug Dev Res, 65:55-75. (Pubitemid 41568621)
11. Gu CH, Li H, Levons J, Lentz K, Gandhi RB, Raghavan K et al. (2007). Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res, 24:1118-1130. (Pubitemid 46798891)
12. Deppermann KM, Lode H. (1993). Fluoroquinolones: interaction profile during enteral absorption. Drugs, 45 (Suppl 3):65-72. (Pubitemid 23242918)
13. Neuvonen PJ, Kivistö KT. (1989). The clinical significance of food- drug interactions: a review. Med J Aust, 150:36-40. (Pubitemid 19023459)
14. Humberstone AJ, Porter CJ, Charman WN. (1996). A physicochemical basis for the effect of food on the absolute oral bioavailabilityof halofantrine. J Pharm Sci, 85:525-529. (Pubitemid 26150986)
15. Wagstaff AJ. (2006). Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs, 66:1881-1901. (Pubitemid 44596199)
16. Novartis. (2006). In US Prescribing Information. Pharmaceuticals Corporation, Novartis, East Hanover, NJ.
17. Wu CY, Benet LZ. (2005). Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res, 22:11-23. (Pubitemid 40558141)
18. Young AM, Audus KL, Proudfoot J, Yazdanian M. (2006). Tetrazole compounds: the effect of structure and pH on Caco-2 cell permeability. J Pharm Sci, 95:717-725.
19. Jonkman JH, van der Boon WJ, Balant LP, Le Cotonnec JY. (1985). Food reduces the rate but not the extent of the absorption of theophylline from an aqueous solution. Eur J Clin Pharmacol, 28:225-227.
20. Lee KJ, Johnson N, Castelo J, Sinko PJ, Grass G, Holme K et al. (2005). Effect of experimental pH on the in vitro permeability in intact rabbit intestines and Caco-2 monolayer. Eur J Pharm Sci, 25:193-200. (Pubitemid 40725048)
21. Mäntylä R, Männistö P, Nykänen S, Koponen A, Lamminsivu U. (1983). Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. Eur J Clin Pharmacol, 24:227-230. (Pubitemid 13147716)
22. Avdeef A. (2001). Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem, 1:277-351.
23. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL et al. (1990). Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res, 7:756-761. (Pubitemid 20278376)
24. Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, Dressman JB. (1998). Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res, 15:698-705. (Pubitemid 28275645)
25. JRH Biosciences I. (2000). Hanks' Balanced Salt Solution (HBSS)- MSDS Vol. 2005. JRH Biosciences, Inc., Lenexa, KS.
26. Levis KA, Lane ME, Corrigan OI. (2003). Effect of buffer media composition on the solubility and effective permeability coefficient of ibuprofen. Int J Pharm, 253:49-59. (Pubitemid 36197830)
27. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS et al. (2004). Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm, 1:85-96.
28. Varma MV, Panchagnula R. (2005). pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ. J Pharm Sci, 94:2632-2643. (Pubitemid 43265387)
29. Serajuddin AT, Sheen PC, Mufson D, Bernstein DF, Augustine MA. (1986). Preformulation study of a poorly water-soluble drug, alphapentyl- 3-(2-quinolinylmethoxy)benzenemethanol: selection of the base for dosage form design. J Pharm Sci, 75:492-496. (Pubitemid 16083647)
30. Crison JR, Weiner ND, Amidon GL. (1997). Dissolution media for in vitro testing of water-insoluble drugs: effect of surfactant purity and electrolyte on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulfate. J Pharm Sci, 86:384-388. (Pubitemid 27113776)
31. Li J, Carr PW. (1997). Accuracy of empirical correlations for estimating diffusion coefficients in aqueous organic mixtures. Anal Chem, 69:2530-2536.
32. Poling BE, Prausnitz JM, O'Connell JP. (2003). The Properties of Gases and Liquids. McGraw-Hill Companies, Inc., New York.
33. Oh DM, Curl RL, Amidon GL. (1993). Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res, 10:264-270. (Pubitemid 23041742)
34. Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413-420.
35. Kokate A, Li X, Williams PJ, Singh P, Jasti BR. (2009). In silico prediction of drug permeability across buccal mucosa. Pharm Res, 26:1130-1139.
36. Campbell MJ. (2001). Statistics at Square Two: Understanding Modern Statistical Applications in Medicine. BML Publishing group, London.
37. Blume HH, Schug BS. (1999). The biopharmaceutics classification system (BCS): class III drugs-better candidates for BA/BE waiver? Eur J Pharm Sci, 9:117-121. (Pubitemid 30012067)
38. Pao LH, Zhou SY, Cook C, Kararli T, Kirchhoff C, Truelove J et al. (1998). Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-administration: relationship with region-dependent intestinal absorption. Pharm Res, 15:221-227. (Pubitemid 28144233)
39. Lee KH, Xu GX, Schoenhard GL, Cook CS. (1997). Mechanisms of food effects of structurally related antiarrhythmic drugs, disopyramide and bidisomide in the rat. Pharm Res, 14:1030-1038. (Pubitemid 27371403)
40. Cook CS, Zhang L, Osis J, Schoenhard GL, Karim A. (1998). Mechanism of compound- and species-specific food effects of structurally related antiarrhythmic drugs, disopyramide and bidisomide. Pharm Res, 15:429-433. (Pubitemid 28175124)
41. Marathe PH, Greene DS, Kollia GD, Barbhaiya RH. (1998). Evaluation of the effect of food on the pharmacokinetics of avitriptan. Biopharm Drug Dispos, 19:381-394. (Pubitemid 28393858)
42. Serajuddin AT, Pudipeddi M. (2002). Salt-selection strategies. In Handbook of Pharmaceutical Salts. Stahl HP, Wermuth CG, eds. Wiley-VCH, Zurich, Switzerland and Weinheim, Germany, pp. 135-160
43. Kararli TT. (1995). Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos, 16:351-380.
44. Hörter D, Dressman JB. (2001). Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev, 46:75-87.
45. Lindenberg M, Kopp S, Dressman JB. (2004). Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm, 58:265-278. (Pubitemid 39037234)
46. Melander A, Stenberg P, Liedholm H, Scherstén B, Wåhlin-Boll E. (1979). Food-induced reduction in bioavailability of atenolol. Eur J Clin Pharmacol, 16:327-330. (Pubitemid 10212152)
47. Buice RG, Subramanian VS, Duchin KL, Uko-Nne S. (1996). Bioequivalence of a highly variable drug: an experience with nadolol. Pharm Res, 13:1109-1115. (Pubitemid 26259016)
48. Tavelin S, Taipalensuu J, Söderberg L, Morrison R, Chong S, Artursson P. (2003). Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm Res, 20:397-405. (Pubitemid 36288368)
49. Pan HY, DeVault AR, Brescia D, Willard DA, McGovern ME, Whigan DB et al. (1993). Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol, 31:291-294. (Pubitemid 23187446)
50. Beermann B, Midskov C. (1986). Reduced bioavailability and effect of furosemide given with food. Eur J Clin Pharmacol, 29:725-727. (Pubitemid 16155749)
51. Welty DF, Siedlik PH, Posvar EL, Selen A, Sedman AJ. (1994). The temporal effect of food on tacrine bioavailability. J Clin Pharmacol, 34:985-988.
52. Caille G, du Souich P, Besner JG, Gervais P, Vezina M. (1990). Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med, 89:838.
53. Aoyagi N, Kaniwa N, Ogata H. (1990). Effects of food on bioavailability of two indomethacin capsules containing different sizes of particles. Chem Pharm Bull, 38:1338-1340. (Pubitemid 20290831)
54. Pade V, Stavchansky S. (1997). Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res, 14:1210-1215. (Pubitemid 27432545)
55. Du Souich P, Lery N, Lery L, Varin F, Boucher S, Vezina M et al. (1990). Influence of food on the bioavailability of diltiazem and two of its metabolites following the administration of conventional tablets and slow-release capsules. Biopharm Drug Dispos, 11:137-147. (Pubitemid 20164632)
56. Levine MA, Walker SE, Paton TW. (1992). The effect of food or sucralfate on the bioavailability of S(+) and R(-) enantiomers of ibuprofen. J Clin Pharmacol, 32:1110-1114. (Pubitemid 23033664)
57. Salama NN, Scott KR, Eddington ND. (2004). DM27, an enaminone, modifies the in vitro transport of antiviral therapeutic agents. Biopharm Drug Dispos, 25:227-236. (Pubitemid 39076896)
58. Taylor S, Pereira AS. (2001). Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect, 77:4-11. (Pubitemid 32142781)
59. Beermann B, Groschinsky-Grind M. (1978). Gastrointestinal absorption of hydrochlorothiazide enhanced by concomitant intake of food. Eur J Clin Pharmacol, 13:125-128. (Pubitemid 8346372)
60. Terhaag B, Gramatte T, Hrdlcka P, Richter K, Feller K. (1991). The influence of food on the absorption of diclofenac as a pure substance. Int J Clin Pharmacol Ther Toxicol, 29:418-421.